Impact of statins on progression of coronary artery calcium composition and density as assessed by noncontrast CT

他汀类药物对冠状动脉钙化成分和密度进展的影响(通过非增强CT评估)

阅读:1

Abstract

The effect of statins on progression of coronary artery calcium (CAC) density as measured by noncontrast computed tomography (CT) remains unknown. We examined the association of statin therapy with temporal changes in compositional calcium density using quantitative assessment of CAC scoring CT. This was a retrospective, single-center study of asymptomatic individuals undergoing serial CAC scoring CT. Scans were analyzed using a fully automated deep learning model, with quantification of total CAC volume and volumes of calcium compositional subtypes stratified by Hounsfield unit (HU) density: 130-199; 200-299; 300-399; ≥400 HU. Of 316 patients (58.4 ± 10.1 years; 49.1% male) with CAC present at baseline and rescanned at a mean interval of 3.8 ± 1.7 years, 175 (55.4%) patients were statin-treated and 141 (44.6%) patients were statin-naive. In patients exhibiting only low-density calcium (130-199 HU) at baseline, statin therapy was associated with a temporal decrease in CAC volume (β - 0.05[-0.09 to - 0.02]; p < 0.05). Among patients with ≥ 2 calcium compositional subtypes at baseline, statin therapy was associated with a greater temporal increase in volumes of each density stratum (130-199 HU: β 0.05[0.00-0.11]; 200-299 HU: β 0.11[0.07-0.14]; 300-399 HU: β 0.11[0.07-0.16]; ≥400 HU: β 0.11[0.06-0.16]; all p < 0.05). Similar results were observed for changes in relative proportions of each density stratum (all p < 0.001). In asymptomatic individuals undergoing serial CAC scoring CT, statin therapy was associated with a shift toward denser calcium, considered a more stable phenotype. Assessment of CAC density may capture more unique aspects of plaque progression and stability beyond traditional CAC scoring.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。